Loading...
XSTOSANION
Market cap82mUSD
Dec 20, Last price  
8.12SEK
1D
0.62%
1Q
68.12%
Jan 2017
-79.64%
IPO
69.05%
Name

Saniona AB

Chart & Performance

D1W1MN
XSTO:SANION chart
P/E
—
P/S
53.95
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.28%
Rev. gr., 5y
-21.05%
Revenues
17m
+10.19%
7,765,92913,640,75421,718,00013,630,00074,921,00020,692,00054,884,0002,658,0008,198,00010,478,00015,283,00016,840,000
Net income
-96m
L-60.95%
00-5,908,000-22,947,0002,217,000-49,189,000-41,059,000-75,788,000-73,430,000-410,898,000-245,357,000-95,810,000
CFO
-86m
L-69.62%
0-3,748,000-7,958,000-28,820,0007,953,000-57,339,000-22,920,000-98,469,000-174,713,000-345,038,000-281,537,000-85,531,000
Earnings
Feb 27, 2025

Profile

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
URL
https://saniona.com/
IPO date
Apr 22, 2014
Employees
23
Domiciled in
DK
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
16,840
10.19%
15,283
45.86%
10,478
27.81%
Cost of revenue
5,059
100,875
399,597
Unusual Expense (Income)
NOPBT
11,781
(85,592)
(389,119)
NOPBT Margin
69.96%
Operating Taxes
(8,470)
(6,610)
(7,482)
Tax Rate
NOPAT
20,251
(78,982)
(381,637)
Net income
(95,810)
-60.95%
(245,357)
-40.29%
(410,898)
459.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
(173)
321
BB yield
0.06%
-0.05%
Debt
Debt current
5,485
5,822
6,799
Long-term debt
72,095
86,586
109,770
Deferred revenue
Other long-term liabilities
2,464
2,391
Net debt
46,618
(23,212)
(261,749)
Cash flow
Cash from operating activities
(85,531)
(281,537)
(345,038)
CAPEX
(129)
(985)
(1,484)
Cash from investing activities
(129)
6,843
43,162
Cash from financing activities
(7,967)
(20,521)
50,596
FCF
22,350
(72,931)
(375,265)
Balance
Cash
30,962
111,707
356,855
Long term investments
3,913
21,463
Excess cash
30,120
114,856
377,794
Stockholders' equity
(849,743)
(760,553)
(531,262)
Invested Capital
901,676
897,035
910,397
ROIC
2.25%
ROCE
22.68%
EV
Common stock shares outstanding
74,537
73,731
73,726
Price
4.01
30.83%
3.07
-65.37%
8.85
-57.04%
Market cap
298,893
32.26%
225,985
-65.36%
652,473
-34.63%
EV
345,511
202,773
390,724
EBITDA
21,432
(77,774)
(380,446)
EV/EBITDA
16.12
Interest
24,932
14,709
10,848
Interest/NOPBT
211.63%